mFOLFIRI + nimotuzumab

mFOLFIRI + nimotuzumab is a combination therapy used primarily in the treatment of advanced or metastatic colorectal cancer. The regimen consists of "modified FOLFIRI" (mFOLFIRI), which includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan, combined with nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). - **mFOLFIRI** is a chemotherapy protocol where the doses or administration schedule may be adjusted from standard FOLFIRI to improve tolerability. Folinic acid enhances 5-FU activity; 5-FU disrupts DNA synthesis as an antimetabolite; irinotecan inhibits topoisomerase I, preventing DNA replication[6][8][10]. - **Nimotuzumab** binds to EGFR on tumor cells, blocking ligand binding and downstream signaling pathways that promote cell proliferation and survival. It is less likely than other anti-EGFR antibodies to cause severe skin toxicity due to its intermediate affinity for EGFR[1][2]. This combination aims to enhance antitumor efficacy by pairing cytotoxic chemotherapy with targeted inhibition of EGFR signaling. Clinical studies suggest that adding nimotuzumab to chemotherapy may increase response rates and disease control in advanced colorectal cancer without significantly increasing toxicity compared to chemotherapy alone[1][3].

Other names

modified FOLFIRI plus nimotuzumabmFOLFIRI and nimotuzumab combination